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Abstract
The dehydrogenation of 24R,25R-varanoyl-CoA, the physiological intermediate formed during the peroxisomal break-
down of the bile acid intermediate trihydroxycoprostanic acid, was studied in human liver. The reaction appeared to be
catalyzed by two different enzymes. A first one, present in the cytosol, did not discriminate between the four possible
varanoyl-CoA isomers and did not require the CoA moiety. The second enzymic activity was associated with peroxisomes
and acted only on the 24R,25R-isomer, in which the 24-hydroxy group possesses the D-configuration. The D-specific
dehydrogenase is part of a 79 kDa protein which represents the human counterpart of a recently discovered second
 .multifunctional protein in rat liver peroxisomes, named multifunctional protein 2 MFP-2 . Human MFP-2, like its rat
 .counterpart, is also responsible for the formation by hydratation of 24R,25R-varanoyl-CoA.
A deficiency of MFP-2 in Zellweger liver could be demonstrated immunologically by using antibodies against the rat
enzyme and enzymically — after removal of the cytosol — by using 24R,25R-varanoyl-CoA. The gene coding for MFP-2
was mapped to chromosome 5q2.3. q1997 Elsevier Science B.V. All rights reserved.
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1. Introduction
A wide range of aliphatic carboxylates can be
degraded in peroxisomes through b-oxidation.
Abbreviations: BAC, bacterial artificial chromosome; DAPI,
4X,6-diamino-2-phenylindole; FAB, fast atom bombardment;
FISH, fluorescent in situ hybridisation; MFP, multifunctional
protein; PAGE, polyacrylamide gel electrophoresis.
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Physiologically important substrates include very long
chain fatty acids, medium- and long chain dicar-
boxylic fatty acids, arachidonic acid derivatives
 .prostaglandins, thromboxanes, leukotrienes , 2-
methyl branched isoprene-derived fatty acids e.g.
pristanic acid 2,6,10,14-tetramethylpentadecanoic
.. acid and bile acid intermediates e.g. di- and trihy-
. w xdroxycoprostanic acids 1–3 . As mitochondrial b-
oxidation, peroxisomal b-oxidation of straight chain
acyl-CoAs proceeds via four sequential steps: an
oxidation step gives rise to a 2-enoyl-CoA which is
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then hydratated in a second reaction; the formed
3-hydroxyacyl-CoA is subsequently dehydrogenated
to a 3-ketoacyl-CoA, which is thiolytically cleaved
during the fourth reaction. The first step is catalyzed
w xby an acyl-CoA oxidase 4 . The second and third
reactions are catalyzed by a multifunctional protein
 .called MFP-1; see further , which possesses besides
2-enoyl-CoA hydratase and 3-hydroxyacyl-CoA de-
hydrogenase activity also D3,D2 enoyl-CoA iso-
w xmerase activity 5,6 . The last step is carried out by a
w x3-ketoacyl-CoA thiolase 7 .
Recent findings suggest that the structurally differ-
ent substrates mentioned above are not degraded by
 .one b-oxidation pathway with a broad specificity
but by separate systems with a limited substrate
. w xspectrum 1 . In rat liver, besides the inducible acyl-
CoA oxidase, referred to as palmitoyl-CoA oxidase,
two other oxidases have been discovered, isolated
w xand cloned 8–12 . One of them, called pristanoyl-
CoA oxidase, acts mainly on 2-methyl-branched fatty
w xacids 9,10 . The other one is more specific for the
bile acid intermediates di- and trihydroxycoprostanic
acids and was named trihydroxycoprostanoyl-CoA
w xoxidase 8,10 . In man, in addition to the oxidase
resembling the rat palmitoyl-CoA oxidase, a second
enzyme, called branched chain acyl-CoA oxidase,
was found which acts on 2-methyl-branched com-
w xpounds and bile acid intermediates 13 . The bio-
chemical properties of this enzyme, together with its
primary amino acid sequence indicate that the
branched chain acyl-CoA oxidase is the human coun-
terpart of the rat trihydroxycoprostanoyl-CoA oxidase
w x11,14 .
Also the second and third peroxisomal b-oxidation
reactions are catalyzed by multiple enzymes in rat
liver. More thorough investigation of the 3-hydroxy-
acyl-CoA dehydrogenases, combined with the cloning
of one of them, demonstrated the presence of two
w xmultifunctional proteins 15,16 . One of them was
identical to the above mentioned inducible MFP-1,
the other one was named multifunctional protein 2
 .MFP-2 . In contrast to MFP-1, which produces L-3-
hydroxyacyl-CoAs and is presumably involved in the
degradation of straight chain fatty acids, MFP-2 pro-
w xduces D-3-hydroxyacyl-CoAs 16 . The 3-hydroxy-
acyl-CoA derivative, formed during the peroxisomal
degradation of trihydroxycoprostanic acid referred to
. 2as varanoyl-CoA , has the 24R,25R configuration
w xas shown by Une et al. 17–19 . The 3-hydroxy group
 .designated as 24R of this isomer has the D configu-
ration. The 24R,25R-varanoyl-CoA isomer is formed
 .hydration and dehydrogenated by rat MFP-2. MFP-1
however also acts on varanoyl-CoA, but on the 24S-
isomers, forming the 24S,25S-isomer while dehydro-
w xgenating the 24S,25R-isomer 16,22 . These data in-
dicate that MFP-2 and not MFP-1 is involved in bile
acid synthesis, a conclusion supported by similar
w xfindings reported by Xu and Cuebas 23 .
Also for the last step, evidence has been provided
for the existence of different thiolases in the rat
w x24–26 , although their substrate spectrum has not
been analyzed.
A search of data banks revealed a high similarity
of rat liver MFP-2 with a protein first described as a
17b-estradiol type IV dehydrogenase and isolated
w xfrom porcine endometrium 27 . Rat liver MFP-2 also
w xpossesses 17b-estradiol dehydrogenase activity 16
and like the porcine 17b-estradiol dehydrogenase, it
consists of multiple domains: an N-terminal short
chain alcohol dehydrogenase domain that harbors the
17b-hydroxysteroid and 3-hydroxyacyl-CoA dehy-
drogenase activity, a central 2-enoyl-CoA hydratase
domain and a C-terminal domain that displays ho-
w xmology to the sterol carrier protein-2 16,28,29 .
These results indicate that rat MFP-2 and the porcine
17b-estradiol dehydrogenases are similar enzymes.
The role of MFP-2 in steroid metabolism is un-
clear. The dehydrogenase activity of purified rat
MFP-2 towards varanoyl-CoA is approx. 300-fold
w xhigher than towards estradiol 16 and the V of themax
crotonase activity of the bacterially expressed porcine
protein is more than 20 000-fold higher compared to
w xits estradiol dehydrogenase activity 29 . These data,
the presence of different 17b-estradiol dehydroge-
 w x .nases in mammalian tissues see 29 for refs. and
the homology of the short alcohol dehydrogenase
domain in these proteins with that of the peroxisomal
multifunctional b-oxidation proteins of Saccha-
2 Originally the 24R,25S-varanic acid isomer was proposed as
w xphysiological intermediate 17,18 . Based on new experimental
w xevidence 19 and stereochemical synthesis of the different iso-
w xmers 20,21 , the initial assignments of the 24R,25S and 24R,25R
isomers should be inversed.
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w x w xromyces cere˝isiae 30 and Candida tropicalis 31 ,
suggest that 17b-estradiol might not be a physio-
logical substrate.
The presence of two MFPs will have important
consequences for the diagnosis of peroxisomal disor-
ders in man with isolated b-oxidation enzyme defi-
w xciencies 32–38 . In some of these patients, there is
an accumulation of very long chain fatty acids but
normal levels of bile acid intermediates and vice
versa, suggesting the presence of a specific defect in
fatty acid degradation and bile acid synthesis, respec-
tively. Elucidation of the primary enzyme defect in
these patients has proved difficult, since, except for
the acyl-CoA oxidases, measurement of the individ-
ual peroxisomal b-oxidation enzymes requires the
prior separation of peroxisomal and mitochondrial
proteins acting on the same acyl-CoA substrates. In
rat liver the 24R,25R-isomer of varanoyl-CoA is
formed and dehydrogenated exclusively by MFP-2
and not by MFP-1 or the mitochondrial 3-hydroxy-
w xacyl-CoA dehydrogenases 16 . Hence the idea to use
this substrate in order to reveal the presence of
MFP-2 in man and to develop an assay to measure its
3-hydroxyacyl-CoA dehydrogenase activity.
The human counterpart of rat MFP-2 has been
neither isolated, nor measured so far. Recently, its
cDNA was cloned by means of its similarity to the
type IV 17b-estradiol dehydrogenase from porcine
w xendometrium 39 , without knowing, however, that
the enzyme is involved in bile acid formation. The
primary amino acid sequence of the human protein
shows 86% identity to the rat enzyme, implicating
w xthat the antibodies raised against rat MFP-2 16
likely cross-react with the human enzyme. Indeed, in
human liver homogenates a cross-reactive band of the
 .appropriate size was seen see further . In order to
 .further characterize the MFP-2 and MFP-1 activi-
ties in man, we investigated the dehydrogena-
tionrdehydratation of the varanoyl-CoA isomers in
human liver.
2. Materials and methods
2.1. Materials
D,L-b-hydroxybutyryl-CoA, acetoacetyl-CoA and
crotonyl-CoA were obtained from Sigma and 17b-
estradiol from Serva. Racemic 3-hydroxypalmitoyl-
CoA, racemic varanoyl-CoA and octenoyl-CoA were
w xprepared as described before 15,16 . The four
stereoisomers of varanoyl-CoA were purified and
w xidentified as described earlier 16 . Rat MFP-2 was
w xpurified as described before 15 . Antisera against rat
MFP-1 and rat MFP-2 were raised in rabbits as
w xdescribed 16,22 .
Human liver tissue was kindly provided by Drs. F.
Penninckx and R. Aerts, Department of Abdominal
 .Surgery University of Leuven . The tissue samples
were obtained either after liver segment resection for
hepatic tumors, or from livers prepared for transplan-
tation. Postmortem liver samples from patients with
Zellweger syndrome were provided by Dr. R.J.A.
 .Wanders Academisch Ziekenhuis, The Netherlands .
Approval was granted by the Ethics Committee of
our University. Human skin fibroblasts were grown
w xas described before 40 .
2.2. Preparation of homogenates and subcellular
fractions and partial purification of human MFP-2
Human liver samples were cut in small pieces,
 .homogenized in 0.25 M sucrose, 0.1% vrv ethanol,
1 mM EDTA, pH 7.2, and fractionated by differential
centrifugation into a nuclear, heavy mitochondrial,
light mitochondrial, microsomal, and cytosolic frac-
w xtion as described for rat liver 41 . Peroxisomes were
purified from the light mitochondrial fraction by sub-
 .sequent centrifugation in Percoll Pharmacia and
 . w xNycodenz Nycomed gradients 41 and were sub-
 .fractionated into matrix proteins S fraction , periph-1
 .eral membrane proteins S fraction and integral2
 . w xmembrane proteins P fraction 15 . Protein and2
marker enzymes were determined as described previ-
w xously 13,41 .
For the partial purification of MFP-2, proteins
released from the peroxisomes by high salt treatment
 .S fraction were concentrated against solid poly-2
 .ethylene glycol 20 000 Da and dialysed overnight
against 20 mM K-phosphate buffer pH 7.0. After
centrifugation the protein solution was applied to a
cation exchange sulfopropyl column Protein PAK
.Glass SP-5PW, 8=75 mm; Nihon Waters Ltd. .
Bound proteins were eluted with a phosphate gradient
w xas described previously 16 . The flow rate was 0.8
mlrmin and fractions of 1.6 ml were collected.
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2.3. 3-Hydroxyacyl-CoA dehydrogenase and 2-enoyl-
CoA hydratase measurements
Dehydrogenase activities of homogenates and sub-
cellular fractions were measured fluorimetrically by
following the NADH formation at a substrate concen-
w xtration of 25 mM 15 . Substrates were D,L-3-hy-
droxybutyryl-CoA, D,L-3-hydroxypalmitoyl-CoA,
varanoyl-CoA racemic or one of the four stereoiso-
.  .mers and 17b-estradiol dissolved in ethanol . Re-
 .ductase activity reversed reaction was measured
w xusing acetoacetyl-CoA as substrate 15 .
Hydratase activities were measured as the hydra-
tion of crotonyl-CoA and 2-trans-octenoyl-CoA or in
the reverse direction for varanoyl-CoA isomers as
w xdescribed previously 16 .
In order to remove an interfering activity present
 .in the cytosol, liver samples 20 to 40 mg were
homogenized by means of a Dounce homogenizer in
2 ml of 0.25 M sucrose, 5 mM Mops, pH 7.2, 1 mM
EDTA pH 7.2, 1 mM DTT and 0.5 mM PMSF
followed by centrifugation at 100 000=g for 40
min. The pellet was resuspended in 0.4 ml of ho-
mogenisation medium.
2.4. SDS-PAGE and Western blotting
SDS-PAGE and immunoblotting were done as de-
w xscribed before 15 .
2.5. Chromosome mapping
Six bacterial artificial chromosomes containing the
 .human MFP-2 gene MFP-2 were isolated from a
commercial genomic BAC library Research Genet-
.ics by screening with EcoRIrXhoI fragments of the
w xrat MFP-2 cDNA 16 . The presence of the MFP-2
gene in the BAC DNA was confirmed by Southern
blot analysis. BAC DNA was digested with restric-
 .tion endonucleases, electrophoresed on a 0.7% wrv
agarose gel, transferred to Hybond Nq and hy-
bridized with the rat cDNA as a probe following
standard procedures. One common restriction frag-
ment was positive in all six BACs. Further proof of
their identity was obtained by PCR and DNA se-
quencing. BAC DNA was labeled with biotine-16-
 .dUTP Boehringer by nick translation using a com-
 .mercial kit Life Technologies as described by Chaf-
w xfanet et al. 42 . Metaphase spreads were prepared
from phytohemagglutinin-stimulated human periph-
eral blood lymphocytes cultured for 72 hours. Prior to
FISH, slides were treated with RNase A and pepsin
w x as described 43 . Human Cot-1 DNA Life Tech-
.nologies was used as a competitor for repetitive
sequence. Denaturation of the slides and probes, hy-
bridization and subsequent cytochemical detection of
the hybridization signals were performed as previ-
w xously described 42 . The chromosomes were coun-
terstained with DAPI and the slides were mounted in
Vectashield mounting medium Vector laboratories,
.Inc. . The signal was visualised by digital imaging
microscopy by using a cooled charge-coupled device
 .camera Photometrics Ltd. . A GrQ banding pattern
was generated by using the DNA counterstain DAPI.
Merging and pseudocoloring were performed with
 .the Smartcapture software Vysis .
3. Results and discussion
Due to the presence of the 25-methyl and the
24-hydroxy groups, four stereoisomers of varanoyl-
CoA are possible. In rat liver racemic varanoyl-CoA
is dehydrogenated mainly by peroxisomes the
24R,25R and 24S,25R-isomer being recognized by
.MFP-2 and MFP-1, respectively and not by mito-
w xchondria 15,16,22 . In a first series of experiments
we, therefore, investigated the dehydrogenation of
racemic varanoyl-CoA in homogenates and subcellu-
lar fractions from human liver. As can be seen from
Fig. 1 the varanoyl-CoA dehydrogenase activity fol-
lowed a peroxisomal distribution, the 3-hydroxy-
butyryl-CoA dehydrogenase and acetoacetyl-CoA re-
ductase activities followed a distribution that was
mainly mitochondrial and the 3-hydroxypalmitoyl-
CoA dehydrogenase activity followed an intermediate
distribution between that of peroxisomes and mito-
chondria.
Further separation of the light mitochondrial frac-
tion by means of Percoll and Nycodenz gradient
centrifugation, showed that the distribution of the
varanoyl-CoA dehydrogenase activity followed that
 .of the peroxisomal marker, catalase Fig. 2 . As
expected from the differential centrifugation experi-
ments, when using a short straight chain substrate
 .3-hydroxybutyryl-CoA or acetoacetyl-CoA the de-
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Fig. 1. Subcellular dirstribution of 3-hydroxyacyl-CoA dehydro-
genase activities in normal human liver. Fresh human liver was
homogenized and fractionated by differential centrifugation into a
 .  .nuclear N , a heavy mitochondrial M , a light mitochondrial
 .  .  .L , a microsomal P and a soluble S fraction. Marker enzymes
and 3-hydroxyacyl-CoA dehydrogenase activities were measured
 .in each fraction. a, glutamate dehydrogenase mitochondria ; b,
 .  .catalase peroxisomes ; c, acid phosphatase lysosomes ; d, glu-
 .cose-6-phosphatase endoplasmic reticulum ; e, lactate dehydro-
 .genase cytosol ; f, varanoyl-CoA dehydrogenase; g, 3-hydroxy-
palmitoyl-CoA dehydrogenase; h, 3-hydroxybutyryl-CoA dehy-
drogenase; i, acetoacetyl-CoA reductase. Results are expressed as
relative specific activities versus percentage of total protein.
Relative specific activity is defined as the percentage of total
recovered activity present in a particular fraction divided by the
corresponding percentage of total protein. Recoveries were be-
 .tween 84 and 109%, except for lactate dehydrogenase 149% .
Racemic mixtures of varanoyl-CoA, 3-hydroxypalmitoyl-CoA and
3-hydroxybutyryl-CoA were used to measure the dehydroge-
nases.
 .hydrogenase or reductase activity, recovered in the
light mitochondrial fraction, was associated mainly
 .with the mitochondria Fig. 2 . The longer straight
chain substrate, 3-hydroxypalmitoyl-CoA, was dehy-
drogenated by both mitochondria and peroxisomes
 .Fig. 2 .
In rat liver peroxisomes, MFP-1 and MFP-2 can
both dehydrogenate varanoyl-CoA, although acting
w xon different isomers 16,22 . In order to obtain more
information on the presence of MFP-2 in human
liver, blots of homogenates and the subcellular frac-
tions were incubated with the antiserum raised against
rat MFP-2. The size of the immuno-reactive band
with an estimated mass of 79 kDa and that was
 .enriched in the light mitochondrial fraction Fig. 3 ,
w xcorresponds to that of rat MFP-2 16 and to the mass
w xcalculated from the human cDNA 39 . During fur-
ther purification of the peroxisomes by Percoll and
Nycodenz gradient centrifugation, the distribution of
the immuno-reactive 79 kDa band followed those of
varanoyl-CoA dehydrogenase and catalase data not
.shown .
In purified peroxisomes, in addition to the 79 kDa
band, other immuno-signals were present at 45 and
 .40 kDa Fig. 3 . In the rat a portion of MFP-2 is
proteolytically cleaved resulting in a separate 17b-hy-
droxysteroid dehydrogenaser3-hydroxyacyl-CoA de-
hydrogenase and a separate 2-enoyl-CoA hydratase
w x16,22 . The 17b-hydroxysteroid dehydrogenaser3-
hydroxyacyl-CoA dehydrogenase which corresponds
to the N-terminal part of MFP-2, forms a doublet at
40 kDa after gel electrophoresis and associates as a
dimer. The C-terminal 2-enoyl-CoA hydratase has a
molecular mass of 45 kDa on gel electrophoresis. The
proteolytic process appears to occur in vivo since the
40 kDa and 45 kDa fragments are found in ho-
mogenates freshly prepared in the presence of a
w xcocktail of proteinase inhibitors 15,16,22 . A similar
proteolysis was described for the porcine protein,
w xgiving rise to 45 kDa and 32 kDa fragments 27 , and
apparently proteolysis occurs also in human liver
In order to proof the identity of the immuno-reac-
 .tive bands with human MFP-2 and its products , the
subperoxisomal localisation of varanoyl-CoA dehy-
drogenase was studied using the 24R,25R-isomer,
followed by partial purification of the activity. As
shown in Table 1, almost no activity was found in the
matrix protein fraction obtained by hypotonic shock.
The major portion of the dehydrogenase activity was
released by high salt treatment. Immunoblotting re-
 .vealed a similar picture Fig. 3 . Surprisingly, when
measuring hydratase activities in the peroxisomal
subfractions, a discrepancy between the dehydratation
of 24R,25R-varanoyl-CoA and enoyl-CoA hydratases
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was noticed 61% of the crotonase and 27% of the
octenoyl-CoA hydratase activities were found in the
.matrix fraction . Since crotonyl-CoA is a poor sub-
w xstrate for rat MFP-2 16,22 , this could suggest that in
human liver, MFP-1 is easier released than MFP-2.
Further separation of the proteins present in the S1
and S2 fractions by cation exchange chromatography
w xsustained this idea. Like in rat 16,22 , the hydratase
and 3-hydroxyacyl-CoA dehydrogenase activities
present in the S2 fraction were resolved in two peaks
 .  .Fig. 4 . The first peak fractions 13-17 was charac-
terized by high octenoyl-CoA hydratase and low
crotonase activities and displayed dehydratase and
dehydrogenase activities with varanoyl-CoA, but only
the 24R,25R-isomer. Crotonase activity was mainly
 .associated with the second peak fractions 19-21
which was also active towards octenoyl-CoA. The
presence of the 79 kDa MFP-2 in the first peak was
evident after immunoblot analysis using anti-rat
w xMFP-2. Like in rat liver 16,22 , a cross-reactive 45
kDa protein, a cleavage product of MFP-2, tends to
elute together with the intact protein upon ion ex-
 .change chromatography Fig. 4 . A 77 kDa protein
cross-reacting with anti-rat MFP-1 was only observed
 .in the second peak data not shown . A similar
 .chromatographic separation of the matrix protein S1
fraction, revealed the presence of one major peak
with high crotonyl-CoAroctenoyl-CoA hydratase ac-
tivities and eluting like MFP-1 confirmed by im-
. w xmunoblot . Similar to rat MFP-1 16,22 , human
MFP-1 displayed 24S,25R-varanoyl-CoA dehydroge-
nase and 24S,25S-varanoyl-CoA dehydratase activi-
Fig. 2. Varanoyl-CoA dehydrogenase distribution during subfrac-
tionation of a light mitochondrial fraction. A light mitochondrial
fraction, prepared by differential centrifugation, was subfraction-
ated by isopycnic centrifugation in an iso-osmotic self-generating
 .Percoll gradient Panel A . Peroxisome-enriched fractions from
the Percoll gradient were subsequently loaded on a three-step
 .Nycodenz gradient Panel B as described in Section 2. The
gradient fractions were analyzed for glutamate dehydrogenase
 .  .  .  .a , catalase b , acid phosphatase c , glucose-6-phosphatase d ,
 .varanoyl-CoA dehydrogenase e , 3-hydroxypalmitoyl-CoA de-
 .  .hydrogenase f , 3-hydroxybutyryl-CoA dehydrogenase g , ace-
 .  .toacetyl-CoA reductase h and protein i . Results are expressed
as percentage of total gradient activity or content present in each
fraction numbered on the abscissa. Recoveries were between 70
and 126%, except for varanoyl-CoA dehydrogenase 50% in
.Percoll gradient and 3-hydroxypalmitoyl-CoA dehydrogenase
 .47% in Nycodenz gradient . 3-Hydroxyacyl-CoA dehydrogenase
activities were measured with the racemic mixtures of varanoyl-
CoA, 3-hydroxypalmitoyl-CoA, and 3-hydroxybutyryl-CoA.
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Table 1
Subperoxisomal distribution of 24R,25R-varanoyl-CoA dehydrogenase in human liver
Fraction 24R,25R-varanoyl-CoA dehydrogenase Catalase Protein
mUrfraction mUrmg protein %rfraction Urfraction Urmg protein %rfraction mgrfraction %rfraction
Peroxisomes 398 13.7 119 4.1 29.0
S1 16.8 2.1 2.7 94.5 11.8 79.8 8.0 34.8
S2 423 101 65.9 13.5 3.2 11.5 4.2 18.2
P2 201 18.6 31.4 9.7 0.9 8.7 10.8 47.0
Peroxisomes were purified from human liver by means of Percoll and Nycodenz gradients and subsequently subfractionated into fractions
 .  .  .enriched in matrix proteins S1 , peripheral membrane proteins S2 and integral membrane proteins P2 . Catalase, 24R,25R-varanoyl-CoA
dehydrogenase and protein content of these fractions were measured as described in Section 2 and related to the values found in the
purified peroxisomes. The data are means of duplicate determinations. Recoveries after subfractionation were 159% for 24R,25R-
varanoyl-CoA dehydrogenase, 99% for catalase and 80% for protein.
ties. Compared to its crotonase activity, these activi-
ties are much lower 2600 fold for the dehydroge-
.  .nase; 75-fold for the hydratase data not shown .
From these data, it appeared that two thirds of
MFP-1 are released during hypotonic shock of human
peroxisomes, and that human MFP-2, as well as
MFP-1, display the same substrate specificity and
stereospecificity as their rat counterparts with regard
to the CoA-esters. We also tried to measure 17b-
estradiol dehydrogenase activity associated with hu-
man MFP-2 but were not able to record such activity.
 .Assuming the same low ratio of 17b-estradiol over
24R,25R-varanoyl-CoA dehydrogenase activity for
human MFP-2 as observed in purified rat MFP-2, the
activity is below the detection limit of our assay,
despite the use of semi-purified preparations.
In a next step we wanted to investigate the pres-
encerabsence of MFP-2 in peroxisomal disorders.
Although 24R,25R-varanoyl-CoA is a selective sub-
 .strate for MFP-2 or its cleavage product , the high
activity observed in the cytosolic fraction when using
 .the racemic isomer was somewhat harassing Fig. 1 .
The relative enrichment of the dehydrogenase activity
in the cytosol was similar to that of catalase. Due to
the more rigid consistency of human liver compared
to rat liver, more damage may occur to the peroxi-
Table 2
Stereospecificity of varanoyl-CoA dehydrogenase activities in homogenates, cytosol and total organelle fractions of livers from healthy
individuals and Zellweger patients. Human liver samples were homogenized and centrifuged in order to recover the organelles.
Varanoyl-CoA dehydrogenase activities were measured in cytosol and organelle fractions by using the four stereoisomers. The isomers
were also used to measure the dehydrogenase activity partially purified from the cytosol. Data are means of duplicate determinations.
n.d.snot detectable.
Sample Fraction Varanoyl-CoA stereoisomer
 .Activity mUrmg of protein
24S,25R 24R,25S 24S,25S 24R,25R
Control liver 1 Soluble extract 1.83 2.90 3.25 3.19
Organelle pellet n.d. n.d. n.d. 3.59
Control liver 2 Soluble extract 1.26 1.82 1.61 2.17
Organelle pellet n.d. n.d. n.d. 4.54
Zellweger 1 Soluble extract 4.82 4.48 5.68 4.39
Organelle pellet n.d. n.d. n.d. n.d.
Zellweger 2 Soluble extract 4.69 3.69 4.26 4.76
Organelle pellet n.d. n.d. n.d. n.d.
Zellweger 3 Soluble extract 3.30 1.98 3.58 3.90
Organelle pellet n.d. n.d. n.d. n.d.
Cytosolic dehydrogenase 72.0 60.9 66.5 72.0
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somes during tissue homogenization, resulting in the
leakage of peroxisomal markers. Human MFP-2, like
w xthe rat counterpart 15,16 , behaves however as a
peripheral membrane proteins, requiring high salt
 .treatment in order to become soluble Table 1 . The
possibility that MFP-1, being easier released from the
peroxisomes, would contribute to the cytosolic vara-
noyl-CoA dehydrogenation is remote given its low
activity towards the 24S,25R-isomer. Therefore, we
assumed that the peroxisomal and cytosolic varanoyl-
CoA dehydrogenase activities resided with different
proteins.
Based on the following lines of evidence, we
conclude that the cytosolic activity is indeed due to a
 .dehydrogenase not related to MFP-2 or MFP-1 .
Firstly, immunoblot analysis of the subcellular frac-
tions and gradient fractions with antibodies raised
against rat MFP-2 revealed a cross-reacting band of
79 kDa in fractions enriched in peroxisomes but in
 .the cytosol no band was visible see Fig. 3 . Sec-
ondly, in contrast to the peroxisomal activity, the
cytosolic activity did not discriminate between the
 .four varanoyl-CoA isomers Table 2 . Thirdly, after
partial purification, using ammonium sulfate precipi-
tation and chromatographic separation on cation ex-
change and hydroxylapatite columns, the major por-
tion of the cytosolic activity was associated with a
protein with a subunit size of approx. 37 kDa. This
protein was also active with varanic acid and trihy-
droxycoprostanoyl-CoA, indicating that the cytosolic
‘varanoyl-CoA’ dehydrogenase activity, is not ex-
erted at the 24-hydroxyl group. Finally, as discussed
in more detail below, the cytosolic dehydrogenase
activity was still measurable in Zellweger liver ho-
mogenates.
This information was used to develop a specific
enzymatic assay for the dehydrogenase activity of
MFP-2 in human liver. A liver homogenate was made
from which the membranes were sedimented at high
g forces. The supernatant was expected to contain the
cytosolic non-specific activity, whereas the activity
associated with MFP-2 was expected to be found in
the membrane pellet. That this was the case is shown
by the following lines of evidence. First by using
anti-rat MFP-2 antibodies, we found an immunoreac-
tive 79 kDa band in the homogenates and in the
membrane fraction whereas the supernatant contained
 .only trace amounts of immuno-reactivity Fig. 5 .
Secondly, the released activity did not discriminate
between the different varanoyl-CoA isomers, whereas
the enzyme associated with the pelleted membranes
recognized only the physiological compound Table
.2 . The fact that we did not find 24S,25R-varanoyl-
CoA dehydrogenase activity due to presence of
.MFP-1 associated with the pellet is not too surpris-
ing. As explained above, MFP-1 is easier released
from peroxisomes and its activity towards varanoyl-
Fig. 3. Subcellular and subperoxisomal distribution of MFP-2 in
normal human liver by immunoblotting. Human liver was sub-
fractionated as described in the legend to Fig. 1. Samples of the
 .subcellular fractions 50 mg of protein were applied on 10-20%
gradient polyacrylamide gels and analysed by immunoblotting by
using affinity-purified anti-rat MFP-2 antibodies a, total ho-
mogenate; b, post-nuclear fraction; c, nuclear fraction; d, heavy
mitochondrial fraction; e, light mitochondrial fraction; f, microso-
.mal fraction; g, cytosolic fraction . Lanes j to m represent
 .subperoxisomal fractions 10 mg of protein each obtained from
purified peroxisomes as described in Table 1. j, total peroxi-
 .somes; k, fraction enriched in matrix proteins S1 ; l, fraction
 .enriched in peripheral membrane proteins S2 ; m, fraction en-
 ..riched in integral membrane proteins P2 . For comparison, in
lanes h, i and n, 2, 10 and 0.5 mg of purified rat MFP-1, purified
rat liver peroxisomes and purified rat MFP-2 proteins were
applied, respectively. The additional bands visible in lanes i and
n correspond to proteolytic fragments of MFP-2. The 45 kDa
protein represents the C-terminal part containing the enoyl-CoA
hydratase domain, while the 40 kDa protein represent the N-
terminal part containing the 3-hydroxyacyl-CoA dehydrogenase
domain. In human and rat liver peroxisomes the sizes of the
proteolytic fragments of MFP-2 are comparable.The migration of
molecular weight markers, their mass expressed in kDa, is indi-
cated at the left side.
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CoA is low. Finally, no deficiency of 24R,25R-
varanoyl-CoA dehydrogenase activity could be shown
in total liver homogenates of Zellweger patients data
.not shown , although MFP-2 was absent by immuno-
 .blotting Fig. 5 . After subjecting the liver samples to
the above described procedure, a severe deficiency
Fig. 4. Separation of human MFP-2 and MFP-1 by cation exchange chromatography. Top. The proteins present in the S2 peroxisomal
subfraction were concentrated, dialysed and injected on a cation exchange column as described in Section 2. Bound proteins were eluted
 .  .by a linearly increasing phosphate gradient 20 to 250 mM, broken line . Fractions of 1.6 ml were collected and assayed for de hydratase
 .  .  .activity with crotonyl-CoA ‘ , octenoyl-CoA I , and 24R,25R-varanoyl-CoA ^ and for 24R,25R-varanoyl-CoA dehydrogenase
 .  .’ . Symbols were omitted when no activity was found. In the first peak fractions, no dehydrogenase or de hydratase activities with the
other three varanoyl-CoA isomers was detectable. The high varanoyl-CoA dehydrogenase activity in fraction 14, compared to hydratase
 .activity, is due to the presence of the 40 kDa N-terminal portion of MFP-2 containing the dehydrogenase domain and the lower amount
 .  .of the 45 kDa C-terminal portion of MFP-2 possessing hydratase activity , as revealed by immunoblotting lower panel; lane c . Bottom:
 .Proteins present in 200 ml of the fractions 12 to 22 top panel were separated by SDS-PAGE and analysed by immunoblotting using
antiserum raised against rat MFP-2. Lanes a to k represent fractions 12 to 22. The position of the molecular weight markers, their mass
expressed in kDa, is indicated at the left side.
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became apparent when analysing the pelleted mate-
rial. The dehydrogenase activities found in the super-
natant fractions of control and Zellweger liver were
 .comparable Table 2 .
Because human liver tissue is not readily available,
we next tried to measure MFP-2 activity in skin
fibroblasts. Although bile acid synthesis occurs in
liver, MFP-2 is not a liver-specific enzyme as shown
w xby immunoblotting of rat tissues 16 and Northern
w xanalysis of human tissues 39 . A likely explanation
Fig. 5. Immunoblot analysis of peroxisomal MFP-2 in post
mortem liver samples and its distribution in the organellar and
soluble fraction of liver homogenates. In panel A, human skin
 .fibroblasts from a healthy individual lane a and small pieces of
 .liver from two patients with Zellweger syndrome lanes b and c
 .and two healthy individuals lanes d and e were homogenized
 .and aliquots 75 mg of protein were analysed by SDS-PAGE
 .10-20% gradient gels followed by immunoblotting with affin-
ity-purified anti-rat MFP-2 antibodies. Migration of the molecular
weight markers, their mass expressed in kDa, is indicated at the
left side. In panel B, liver homogenates were subjected to cen-
trifugation at 100000= g for 40 min. to separate organelles from
soluble proteins. Proteins present in the pellet and supernatant 60
. mg each were subjected to SDS-PAGE 10–20% polyacrylamide
.gradient gels and immunoblotting. Lanes a and b represent the
organellar and soluble proteins, respectively, from normal human
liver. Lanes c and d represent the organellar and soluble proteins
from a liver homogenate of a Zellweger patient. Analysis of liver
of two other patients revealed no signals neither in the organelle
or soluble fractions. Migration of the molecular weight markers,
their mass expressed in kDa, is given at the left side.
Fig. 6. Partial nucleotide sequence of MFP-2 gene. Nucleotide
sequence of part of the human MFP-2 gene was obtained by
direct sequencing of one of the BACs used for mapping. Upper-
case letters indicate the coding sequence found to be identical to
w xnucleotides 973 to 1209 reported by Adamski et al. 39 and that
is situated at the beginning of the hydratase domain of MFP-2.
Lower case letters indicate the exonrintron junctions.
for the extra-hepatic presence is that the enzyme may
be involved in the b-oxidation of 2-methyl-branched
w xfatty acids such as pristanic acid 16 . However, the
abundance of MFP-2 in normal human fibroblasts
 .was not sufficient for immunodetection Fig. 5 or to
prove its presence enzymatically with certainty. As
was the case in liver, a non-specific dehydrogenase
 .was present in the cytosol data not shown .
Finally, because of our interest in peroxisomal
disorders the MFP-2 gene was mapped by FISH. For
this purpose, fragments of the rat MFP-2 cDNA were
used to screen a genomic BAC library. The presence
of the human MFP-2 gene in the positive BAC clones
was proved by Southern blot and by PCR. DNA
sequencing of one clone resulted in a sequence 3
identical to nucleotides 973 to 1209 of the human
w xMFP-2restradiol dehydrogenase type IV cDNA 39 ,
 .flanked by introns Fig. 6 . Exon-intron boundaries
were conform to the consensus rules ending in an AG
w xdoublet and starting with a GT pair 44 . As shown in
Fig. 7, the gene was located to chromosome 5q2.3.
To date, this locus has not been linked to a peroxiso-
mal disorder or another metabolic defect in man.
Our present findings show that the dehydrogenase
component of MFP-2 can be measured in human
liver samples by using 24R,25R-varanoyl-CoA as the
substrate. Due to an aspecific dehydrogenase activity
catalyzed by a cytosolic enzyme, organelles need to
be separated from the cytosol prior to measuring the
3 Sequence submitted to EMBL nucleotide sequence databank
under the accession number EMBL Y11393.
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Fig. 7. Chromosomal assignment of MFP-2. The chromosomal
mapping of MFP-2 was investigated by means of FISH on
normal human metaphase spreads from phytohemagglutinin-
stimulated peripheral blood lymphocytes with biotinylated probes
as described in the Section 2. Chromosomes were DAPI counter-
stained and the images were taken using a cooled CCD device.
With all six BACs fluorescent signals were observed at chromo-
 .some 5q2.3 indicated by arrowheads .
enzyme. Although this constitutes a drawback, sepa-
ration of the organelles from the cytosol is easier than
separation of peroxisomes from mitochondria, a ne-
cessity when measuring peroxisomal or mitochon-
drial b-oxidation enzymes without use of a selective
substrate. Unfortunately, we could not detect a spe-
cific varanoyl-CoA dehydrogenase activity in human
fibroblasts, apparently due to the low abundance of
MFP-2. The dehydration of 24R,25R-varanoyl-CoA
is also catalyzed by MFP-2, implying that 24R,25R-
varanoyl-CoA can be used not only for measuring the
dehydrogenase component but also for the hydratase
component of MFP-2. Due to the lesser sensitivity of
the dehydration assay we were not able, however, to
obtain reliable measurements in human liver.
Not unexpectedly - as is the case for other peroxi-
somal b-oxidation proteins - MFP-2 is severely defi-
cient in generalized peroxisomal disorders. The com-
bined use of antibodies and the proposed assay must
allow for the detection of peroxisomal disorders due
to a single MFP-2 deficiency. Based on the bile acid
spectrum in body fluids as analyzed by FAB-MS and
GC-MS, some likely cases of such deficiency have
been reported, showing elevated levels of varanic
acid and normal levels of very long chain fatty acids
w x33 .
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